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A B S T R A C T   
Background: Accumulating data suggest that the tumour stroma rapidly undergoes dynamic mechanical and 
cellular changes by which creates a supportive milieu to promote disease progression and metastasis. Cytokines 
are reported to play a key role in the modulation of tumour stromal response. 
Methods: The activation of TH17/interleukin (IL)− 17A network in association with tumour stromal proliferative 
and cellular response in samples from 50 patients with colorectal adenoma, 45 with colorectal cancer (CRCs) 
were elucidated with quantitative real-time PCR (q-PCR), immunohistochemistry and double 
immunofluorescence. 
Results: q-PCR results showed that retinoic acid-receptor-related orphan receptor-C, a critical transcriptional 
factor for TH17 cell differentiation, was significantly increased at the adenoma stage and slightly decreased at 
the CRC stage, but was still higher than that at normal controls. The level of TH17 signature cytokine IL-17A was 
shown in an increasing gradient throughout the adenoma-carcinoma sequence. Immunohistochemistry revealed 
an activated proliferative rate evaluated by Ki67 and population expansion of myofibroblasts in the adenoma/ 
CRC stroma. Notably, densities of IL-17A-expressing cells were associated with populations of Ki67-positive cells 
and myofibroblasts in the adenoma/CRC stroma. Finally, CD146-positive stromal cells are an important 
participator for stroma remodelling, double immunofluorescence image demonstrated that IL-17 receptor C, one 
of the key elements for IL-17 receptor complex, was highly expressed in CD146-positive adenoma/CRC stromal 
cells. 
Conclusions: An activated TH17/IL-17A network in the tumour microenvironment is significantly associated with 
dynamic stromal cellular response throughout the adenoma–carcinoma sequence, which might provide a sup-
portive environment for the initiation and progression of CRC.   
1. Introduction 
Colorectal cancer (CRC) is the fourth most frequent malignancy and 
has a high mortality worldwide [1]. Advances of adjuvant chemo-, 
radio- and bioimmunological therapies have improved clinical outcomes 
but, unfortunately, metastasis is observed in approximately 20–25% of 
CRC patients at the time of diagnosis [2] and curative surgery becomes 
impossible in those patients. Thus, to improve the clinical outcomes, 
more research is needed to understand the exact mechanisms of 
progression and metastasis. Recent studies have suggested that during 
the progression and metastasis, the tumour stroma, together with 
extracellular matrix and growth factors synthesize, and angiogenesis, 
undergoes a cellular proliferative and phenotypical change [3–5]. Many 
types of cells i.e., mesenchymal stromal cells (MSCs) and fibroblasts 
differentiate to myofibroblasts and construct a supportive cellular 
milieu to tumour invasion and metastasis by enhancing angiogenesis 
and immunosuppression, regulating tumour-stromal interaction and 
epithelial to mesenchymal transition [6–13]. 
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The cellular proliferative response and phenotypical change in the 
tumour stroma are modulated by microenvironmental elements, in 
which cytokines produced by tumour cells and immune cells play a 
critical role. T helper (TH) 17, a IL-17-expressing CD4 positive TH cell 
subset, has been reported to be deeply involved in the pathogenesis of 
CRC [14]. Its signature cytokine interleukin (IL)− 17A has profound 
biological functions via a IL-17 receptor A (IL-17RA) and IL-17RC 
complex in colorectal inflammatory diseases and CRC [15–17] by mul-
tiple proposed mechanisms [14,18–22]. One of the potential mecha-
nisms is that IL-17 participates in the modulation of phenotypic 
differentiation and remodelling of stromal cellular architecture [22–26]. 
Indeed, several reports have shown that IL-17A stimulates the prolifer-
ation, survival and mobilization of stromal fibroblasts [27,28], through 
a upregulation of the transforming growth factor (TGF)-β receptor to 
enhance the expression of profibrotic genes [29]. Interestingly, TGF-β is 
also a upstream stimulator for TH17 cell differentiation [30,31] and 
increased expression levels of both TGF-β and IL-17A have been previ-
ously found in patents with CRC [32–34], indicating a synergistic effect 
of TGF-β with TH17/IL-17A on the promotion of CRC. Furthermore, 
MSCs within the tumour microenvironment, as the critical player in the 
architecture and regulation of tumour-stromal interaction and epithelial 
to mesenchymal transition (EMT), have been shown to be functionally 
regulated by IL-17A [26,35], in a dose-dependent manner [25,36,37]. 
Sivanathan and colleagues [24] reported that exposure of bone 
marrow-derived MSC with IL-17A could enhance the immunosuppres-
sive properties of MSCs, via the mobilization and recruitment of 
immune-suppressive cells into the tumour microenvironment. These 
findings lead us to hypothesize that a TH17/IL-17A microenvironment 
might contribute to the stromal cellular response in patients with tu-
mours. We have therefore designed this study to investigate the poten-
tial involvement of TH17/IL-17 microenvironment on dynamic stromal 
response along the adenoma – carcinoma sequence. 
2. Materials and methods 
2.1. Biopsies from patients with adenoma and CRC 
Fifty biopsies of colonoscopy resected colorectal adenomas (male/ 
female: 31/19; ages: 43–92 years; Histology, tubular/villous/tubulo-
villous: 33/2/15; low grade dysplasia (LGD)/moderate grade dysplasia 
(MGD)/high grade dysplasia (HGD): 22/24/4; and 45 biopsies of sur-
gical resected CRC (male/female: 39/6; ages: 42–89 years; histology: all 
adenocarcinoma; TNM: I/II/III/IV:7/20/17/1; Node positive/nega-
tive:13/32) collected from at the Departments of Gastroenterology and 
Surgery, University Hospital of North Norway, were included in the 
study according to standardized diagnostic criteria. Biopsies from 15 
subjects (male/female: 10/5; ages: 30–77 years) with normal colonos-
copy and histology served as a normal control group. Biopsies were 
divided into 2 parts: one for gene quantification by quantitative real- 
time PCR (qPCR), another for histology, immunohistochemistry (IHC) 
and double immunofluorescence (DIF) staining were embedded in 
paraffin. Routine haematoxylin and eosin (H&E) for histological diag-
nosis was done at Department of Pathology. The study protocol was 
approved by the local Regional Ethical Committee of Northern Norway 
(REK NORD 06/2004) and executed in compliance with the Declaration 
of Helsinki, written informed consent was obtained from all patients. 
The permission for the storage of human tissues and data were given by 
the Norwegian Department of Health and the Norwegian Bureau of Data 
Surveillance (Norwegian Biobank Register 952/2006). 
2.2. Measurement of TH17 key transcriptional factor retinoic acid- 
receptor-related orphan receptor (ROR)-C and signature cytokine IL-17A 
by quantitative real-time PCR (qPCR) 
ROR-C, a master transcription regulator, has been shown to play a 
central role in the regulation of TH17 cell differentiation [38–40]. In this 
study, we quantified the expression level of ROR-C mRNA as a differ-
entiation index of TH17 cells in the adenoma/CRC microenvironment. 
qPCR was carried out on an ABI-prism 7900 sequence detector with 
TaqMan Gold™ PCR core reagents kit (Applied Biosystems/Roche, 
Branchburg, NJ, USA) in 25 μL volume according to our previously 
published method [41–44]. The primer sequences for ROR-C, IL-17A 
and housekeeping gene (beta-actin) were listed in Table 1. The expres-
sion of ROR-C and IL-17A mRNAs in normal, adenoma and CRC tissues 
were measured by cycle threshold cross point (CT) value relative to that 
of normal mucosa as fold difference (N)= 2-ΔΔCT as described in our 
recent publication [43]. 
2.3. Immunohistochemistry (IHC) 
IHCs for stromal proliferation response, stromal myofibroblasts and 
IL-17A expressing TH17 cells in the adenoma/CRC stroma was per-
formed according to the protocol described in our previous publication 
[4,45,46]. In brief, after deparaffinized, rehydrated and antigen 
retrieval routinely, slides were incubated overnight 4 0C with following 
antibodies: mouse anti-human Ki67 monoclonal antibody (to label 
proliferative rate, 1:70; BD Biosciences Pharmingen, San Diego, CA, 
USA), mouse anti-human smooth muscle actin (SMA)-alpha (Clone 1A4) 
monoclonal antibody (to label myofibroblasts, 1:100; DAKO, Carpin-
teria, CA, USA) and goat anti-IL-17A polyclonal antibody (to label TH17 
cells, 1:100; R&D System; Minneapolis, MN, USA) respectively. Sections 
were developed with a commercial Vectastatin Elite ABC Kit (Vector Lab., 
Burlingame, CA, USA) according to the manufacturer’s instructions and 
our published method [46–48]. 3-Amino-9-ethylcarbazole (AEC; Vector 
Laboratories, Burlingame, CA, USA) was used as chromogen and slides 
were counterstained with Mayer’s haematoxylin. 
The negative control slides for IHCs were performed routinely: (1) 
primary antibodies were substituted with the isotype-matched control 
antibodies; (2) secondary antibody was substituted with phosphate 
buffered saline. All the IHC stained slides were examined under a light 
microscopy (CX31, Olympus Optical Co., LTD, New York, USA). 
2.4. Double IHCs for the examination of proliferative capacity of IL-17A 
expressing cells in the adenoma/CRC stroma 
To examine the proliferative capacity of IL-17A expressing cells in 
the adenoma/CRC stroma, double IHC with Ki67/IL-17A (rabbit poly-
clonal, Santa Cruz Biotechnology, USA) antibodies was performed in the 
adenoma and CRC sections using the EnVision Doublestain System kit 
(DAKO, Carpinteria, CA, USA) according to the manufacturer’s in-
structions and our published method [49]. In brief, the slides were 
incubated overnight at 4ºC with mouse anti-Ki67 antibody after antigen 
retrieval, and then incubated with labelled polymer-horseradish per-
oxidase-anti-mouse and anti-rabbit antibodies for 30 min at room 
Table 1 
Primer/probe sequences of house-keeping gene, ROR-C and IL-17A for quanti-
tative real-time PCR.  
Assay  Primer Sequence 
β-actin TaqMan Forward 5′ TGCCGACAGGATGCAGAAG 3′




ROR-C TaqMan Forward 5′GCACACCGTTCCCACATCTC 3′




IL-17A TaqMan Forward 5′ TGATTGGAAGAAACAACGATGACT 3′
Reverse 5′ ATTGTGATTCCTGCCTTCACTATG 3′
Probe FAM 5′ TGGTGTCACTGCTACTGCTGCTGAGC3′
BHG  
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temperature. Ki67-IR with peroxidase activity was detected with the 
enzyme substrate 3,3′-diaminobenzidine tetrachloride (DAB). After 
quenching the enzyme reaction, the slides were incubated in Double-
stain Block at room temperature for 5 min to block endogenous phos-
phatase. The slides were then incubated with rabbit anti-IL-17A 
antibody (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 2 h at 
room temperature. After washing, the slides were incubated with 
labelled polymer-alkaline phosphatase anti-mouse and anti-rabbit anti-
body for 30 min at room temperature. Fast Red chromogen substrate 
solution was used to visualize IL-7A immunoreactivity (IR). All the 
sections were slightly counterstained with Mayer’s haematoxylin. 
2.5. Double immunofluorescence (DIF) staining 
CD146 expressed in stromal cells promotes cancer cell growth and 
invasion, and induces stromal MSC properties via the activation of EMT 
[50] and angiogenesis [51]. To define the expression of the critical 
subunit of IL-17 receptor (IL-17R) complex, IL-17RC [52], in the stromal 
CD146-positive cells, DIF staining with the antibodies IL-17RC (goat 
polyclonal antibody from Abcam, UK)/CD146 (rabbit polyclonal anti-
body from Thermos Fisher Scientific) were performed according to our 
previously published method [53]. IL-17RA-IR was developed with 
Texas red-conjugated secondary antibody (Jackson ImmunoRearch 
Lab., West Grove, PA, USA), CD146-IR was with fluorescein isothiocy-
anate (FITC)-conjugated secondary antibody (Jackson ImmunoRearch 
Lab., West Grove, PA, USA). Nuclear counterstaining was not applied 
and the stained slides were observed and photographed with a confocal 
microscopy (LSM-700, Carl Zeiss, Jena, Germany) under × 200 
mediate-power fields. Negative controls were performed with (1) pri-
mary antibodies were substituted with the isotype-matched control an-
tibodies; (2) The cross-reactivity was examined by crossing different 
secondary antibodies. 
2.6. Morphometric analysis 
The numbers of Ki67-positive cells and IL-17A-positive cells in the 
stroma were counted in at least 5 five well-orientated fields with 
abundant positive cell distribution from each slide under 400 × high- 
power magnifications. SMA-alpha expressing myofibroblasts were found 
at a very high density in the stroma and were scored with light micro-
scopy using the following criteria: Score 1, 1–25% positive cells; Score 2, 
25–50% positive cells; and Score 3: > 50% positive cells [4,54]. The 
average values were used for the statistical analysis. 
2.7. Statistical analysis 
The expression of ROR-C and IL-17A mRNAs in normal, adenoma 
and CRC tissues were measured by cycle threshold cross point value 
relative to that of normal mucosa as fold difference (N)= 2-ΔΔCT as 
described in our recent publication [43]. All the results were expressed 
as mean ± SEM unless otherwise stated. Statistical significance was 
evaluated by the Mann–Whitney and the Kruskal–Wallis tests. Values of 
P < 0.05 were considered significant. The populations of Ki67-positive 
cells and SMA-positive myofibroblasts in the adenoma/CRC stroma 
was divided into low and high two groups according to the median of 
IL-17A-positive cell density in the stroma, the difference between two 
groups was evaluated by the Mann–Whitney test. 
3. Results 
3.1. TH17 key transcriptional factor ROR-C and signature cytokine IL- 
17A were significantly increased throughout the human adenoma- 
carcinoma sequence 
As shown in Fig. 1A, the levels of TH17 transcriptional factor ROR-C 
mRNA were greatly increased in adenoma and CRC tissues as compared 
with control tissues. Interestingly, the tissue level of ROR-C mRNA at the 
adenoma stage was higher than the CRC stage. Analysis of ROR-C mRNA 
against pathological parameters in patients with adenoma and CRCs has 
been summarized in Table 2 and 3. Data revealed that the levels of ROR- 
C mRNA did not correlate neither with grading degree of dysplasia in 
patients with adenoma, with TNM stages, tumour invasion depth, nor 
node metastasis in patients with CRC. 
qPCR data showed that the tissue expression level of IL-17A mRNA 
was shown in an increasingly gradient throughout the adenoma - 
Fig. 1. Dynamic changes of TH17 key transcriptional factor ROR-C and 
signature cytokine IL-17A transcripts throughout the colorectal adenoma- 
carcinoma sequence. qPCR data showed that the expression level of ROR-C 
mRNA was significantly increased in the adenoma tissues (grey bar in 
Figure A); it remains in a higher in the CRC tissues (black bar in figure A) as 
compared to the controls (white bar in Figure A), but lower than that in the 
adenoma tissues. The expression level of TH17 signature cytokine IL-17A 
mRNA in the adenoma tissues (grey bar in Figure B) as compare to the con-
trol (white bar in Figure B); was significantly increased and even higher in the 
CRC tissues (black bar in Figure B) compared to the adenomas. (Y axes in 
Figs. 3A and B are fold changes relative to normal controls; P values are derived 
from the Mann-Whitney test). 
Table 2 
Analysis of ROR-C and IL-17A mRNA levels against clinicopathological variables 
in patients with adenoma.  
mRNA Grading degree of 
dysplasia 
P1 Histology P2 




9.27 ± 2.52 vs. 4.99 ±
0.50 vs. 4.80 ± 1.67 





31.41 ± 17.09 vs. 
26.12 ± 12.02 
vs.179.3 ± 70.75 
<0.05 31.07 ± 12.71 vs. 35.36 ±
13.96 
>0.05 
P1 values were from the Kruskal-Wallis test; P2 values were from the Man-
n–Whitney test. 
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carcinoma sequence (Fig. 1B). Like the analysis data of ROR-C mRNA, 
the levels of IL-17A mRNA were neither associated with pathological 
parameters of adenomas nor CRCs (Table 2 and 3). 
3.2. IL-17A-positive cells, proliferative rate and myofibroblasts in the 
adenoma/CRC stroma 
Increased IL-17A-positive cells (Fig. 2A–C), proliferative rate 
(labelled by Ki67) (Fig. 2 D–F) and myofibroblasts (labelled by SMA-α, 
Fig. G–I) were observed in the adenoma and CRC stroma as compared 
with the control. 
Counting data confirmed IHC observation. As shown in Table 4, 
populations of Ki67-positive cells, myofibroblasts and IL-17A-positive 
cells in the adenoma/CRC stroma were increased as compared with 
the controls. 
3.3. Proliferative capacity of IL-17A-positive cells in the adenoma and 
CRC stroma 
Double IHCs showed that these IL-17A expressing cells had a high 
Table 3 
Analysis of ROR-C and IL-17A mRNA levels against clinicopathological variables 
in patients with CRC.  
mRNA TNM stage P1 Node involvement P2 
I vs. II vs. III Positive vs. Negative 
ROR- 
C 
3.76 ± 1.29 vs. 3.98 ± 2.50 
vs. 2.77 ± 0.93 





26.98 ± 14.88 vs. 42.91 ±
21.27 vs. 41.78 ± 21.46 
>0.05 41.78 ± 21.46 vs. 
37.28 ± 13.99 
>0.05 
P1 values were from the Kruskal-Wallis test; P2 values were from the Man-
n–Whitney test. 
Fig. 2. Photographic representations of IL-17A-, Ki67- and SMA-alpha-positive cells in the adenoma/CRC stroma As compared with the controls (A), increased 
population of IL-17A-positive cells were observed in the adenoma (B) and CRC (C) stroma. The proliferation labelling index by the Ki67 immunoreactivity was 
increased throughout the normal-adenoma-carcinoma sequence (D-F). Increased population of SMA-alpha expressing myofibroblasts were detected in the adenoma 
(Figure H) and CRC (Figure I) stroma as compared with the controls (Figure G). (A-I: IHC, counterstained with haematoxylin, original magnification 200 ×). 
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proliferative capacity in the active adenoma (Fig. 3A) and CRC stroma 
(Fig. 3B). 
Stromal cellular proliferative response and myofibroblast population 
correlated with IL-17A-positive cell densities in both patients with ad-
enoma and CRC. 
As illustrated in Fig. 4A, analysis revealed that adenoma/CRC pa-
tients with a higher IL-17A-positive cell density tended to have a higher 
Ki67 cell density than those with a lower IL-17A-positive cell density. 
Similar relationship was observed between IL-17A-positive cell densities 
and SMA-positive myofibroblasts in the adenoma/CRC stroma (see 
Fig. 4B). 
3.4. The expression of IL-17RC in CD146-positive stromal cells 
DIF images showed that IL-17RC (Fig. 5A for adenoma, 5D for CRC) 
was expressed in CD146-positive stromal cells (Fig. 5B for adenoma, 5E 
for CRC) in the adenoma (Fig. 5C for merged image) and CRC (Fig. 5F for 
merged image), indicating a possible modulation pathway of IL-17A on 
CD146-positive stromal cells in the adenoma/CRC. 
4. Discussion 
Considerable evidence suggests that TH17/IL-17A plays an essential 
role in the development, progression, and metastasis of human CRC [14, 
18,20,21,55]. Current study has evaluated the correlation between the 
TH17/IL-17A and dynamic response of cellular stroma throughout the 
adenoma-carcinoma sequence. We were able to show that an activated 
TH17/IL-17A milieu was associated with the dynamic stromal cellular 
response in reaction to tumour signals and created a supportive micro-
environment for the disease progression and metastasis. 
To evaluate the dynamic of TH17/IL-17A along the adenoma- 
carcinoma sequence, we have firstly determined dynamic of key tran-
scriptional factor ROR-C for TH17 cell differentiation and TH17 main 
cytokine IL-17A. q-PCR results showed that significantly increased 
expression levels of ROR-C were started from the adenoma stage and 
slightly decreased at the CRC stage, but still higher than the controls. 
Since the promoting effect of IL-17A on the development of CRC has 
been reported [21,52], the current finding might imply that 
TH17/IL-17A is an important element involving in the progression of 
adenoma to CRC in human. Whereas the expression levels of IL-17A 
were continuedly increased from the adenoma stage to the CRC stage. 
Such inconsistent changing trend between transcriptional factor for 
TH17 differentiation and IL-17A levels might suggest that TH17 cell 
differentiation from normal to the adenoma stage is highly activated and 
becomes stable when the CRC is developed. We postulated that the 
Table 4 
Populations of stromal IL-17A-positive cells, Ki67-positive cells and SMA- 
positive myofibroblasts in patients with adenoma and CRC.  
Cells Control Adenoma CRC P 
IL-17A 10.23 ± 0.88 19.97 ± 1.86 28.27 ± 3.28 <0.01 
Ki67 7.0 ± 0.70 26.13 ± 2.98 35.74 ± 4.27 <0.01 
Myofibroblasts 1.29 ± 0.11 2.55 ± 0.12 2.71 ± 0.10 <0.01 
Values of P were from the Kruskal–Wallis test. 
Fig. 3. Double immunohistochemical photograph presentation of proliferative capacity in TH17 cells (labelled by IL-17A immunoreactivity) in the adenoma/CRC 
stroma Double IHC with Ki67/IL-17A antibodies further showed that increased proliferation LI (Ki67 visualized by DAB, Brown colour in Figure B for Adenoma and 
3C for CRC) was frequently observed in TH17 cells (IL-17A visualized by Fast Red, Red colour in Figure B for Adenoma and 3C for CRC), but less in the controls (A). 
(Figure A-C, double immunohistochemistry images, original magnification 400 ×; counterstaining was haematoxylin). (For interpretation of the references to colour 
in this figure, the reader is referred to the web version of this article.) 
Fig. 4. The correlation between IL-17A-positive cell density and Ki67 cell and 
SMA-positive myofibroblasts densities in the adenoma/CRC stroma Adenoma/ 
CRC patients with a higher IL-17A-positive cell density tended to have a higher 
Ki67 cell density than those with a lower IL-17A-positive cell density in the 
adenoma/CRC stroma (A). Similarly, a high IL-17A-positive cell density also 
correlated to a high SMA-positive myofibroblasts in the adenoma/CRC 
stroma (B). 
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cellular source of IL-17A has been altered along the adenoma – carci-
noma sequence. In the adenoma stage, TH17 cells could be the main 
cellular source for IL-17A, however in the CRC stage other cells might 
join the production of IL-17A. For instance, studies have shown that 
IL-17 could be produced from stromal cells such as fibroblast [56] and 
FoxP3-positive regulatory T cells [57], these cells are significantly 
increased and activated in the CRC microenvironment [4,13,48,58,59]. 
Stromal response in reaction to tumorigenesis includes a series 
cellular and functional changes i.e. stromal cell proliferation, population 
expansion and phenotypical differentiation, growth factor production, 
enhanced angiogenesis and extracellular matrix modification [60]. 
Studies have demonstrated that fibroblasts, as the major cell type 
composing the stromal cell population, within the adenoma/CRC stroma 
are greatly activated and differentiated [4]. Studies have also suggested 
that resident fibroblasts in the tumour stroma contribute to a significant 
increased population of SMA-alpha expressing (myofibroblasts) in the 
adenoma/CRC stroma and play a critical biophysical role in cancer in-
vasion and metastasis [58,59,61]. Fibroblast-myofibroblast transition 
significantly contribute to the generation of an inflammatory microen-
vironment that supports the progression and metastasis of CRC [62]. In 
this study, we were able to show that increased proliferative rate of 
stromal cells and stromal myofibroblast populations (a subpopulation of 
fibroblasts) were observed in the adenoma/CRC stroma, suggesting a 
strong stromal response in reaction to the tumorigenesis process. 
The proliferation, migration and expansion of stroma cells are 
regulated by many factors including cytokines [63,64]. McGeachy and 
colleagues have previously shown that IL-17 could significantly promote 
the survival and proliferation of fibroblastic reticular cells in inflamed 
lymph nodes by enhancing their metabolic activity [28]. In this study, 
we found that densities of IL-17A-positive cells correlated either with 
Ki67 positive cells and densities of myofibroblasts in the adenoma/CRC 
stroma. Analysis revealed that the adenoma/CRC patients with higher 
IL-17A expressing cells tended to have a higher proliferative rate and 
population of myofibroblasts in the stroma, suggesting a possible impact 
of IL-17 on myofibroblast expansion in the adenoma/CRC stroma. In 
addition, MSCs are one of the putative cellular sources for stromal fi-
broblasts [65]. There is strong evidence to suggest that MSCs are regu-
lated by their surrounding microenvironmental elements [66]. In which, 
IL-17A has been shown to be a promoting factor for MSCs [26,37]. 
CD146 is a cell membrane protein whose expression has been implicated 
in multiple human cancers. High expression of CD146 is reported in 
stromal MSCs [51,67–69], and involved in the tumour stroma remod-
elling [70]. CD146 has also been hypothesized to be an EMT inducer in 
breast cancer [50], and also participates in the modulation of tumour 
angiogenesis [71]. Recent studies revealed that CD146 could be a 
cellular surface receptor of miscellaneous ligands, including some 
growth factors and extracellular matrixes [72]. Jiang et al. found that 
CD146 is a coreceptor for vascular endothelial growth factor receptor 2 
(VEGFR2) and participates in the regulation of tumour angiogenesis 
[51], Espagnolle et al. reported that CD146 expression on MSCs is 
associated with their vascular smooth muscle commitment [68]. These 
lines of evidence strongly suggest that CD146 is a critical molecule 
involved in the stromal remodelling. We have therefore examined the 
potential pathway of IL-17A on CD146-positive stromal cells. Our data 
showed that IL-17RC was highly expressed in the CD146-positive stro-
mal cells in both the adenoma and CRC stroma. This finding implies a 
possible action pathway for IL-17A on the adenoma/CRC stromal cells. 
Since recent progressions have supportively indicated that TH17/IL-17 
network plays an essential role in promoting CRC progression and 
metastasis, monoclonal antibodies targeting the IL-17/IL-17RA axis has 
been considered as a potential biotherapeutic that might improve the 
efficiency of anti-VEGF therapy in metastatic CRC patients [73]. Indeed, 
Fig. 5. Double immunofluorescence visualize the expression of IL-17RC on CD146-positive cells in the adenoma/CRC stroma Double immunofluorescence images 
showed that IL-17RC-immunoreactivity (visualized by Texas red, red colour) was frequently expressed on CD146-positive cells (visualized by FITC, green colour) in the 
adenoma (arrows in A-C) and CRC (arrows in D-F) stroma. Interestingly, IL-17RC-immunoreactivity could be also observed in tumour associated microvessels 
(arrowhead in Figure A) and CRC epithelium (arrowhead in D) respectively. (Figure A-F, confocal images, original magnification 200 ×; counterstaining was not 
applied). (For interpretation of the references to colour in this figure, the reader is referred to the web version of this article.) 
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we and others have previously demonstrated that administration of 
anti-IL-17A antibody could significantly suppress the development of 
CRC in mice [74,75]. 
Some of the limitations for this study must be discussed here. Firstly, 
we only examined the co-expression of IL-17 in Ki67 positive stromal 
cells and did not look at the co-staining for IL17RC in Ki67 positive 
stromal cells. Which only indicate a possible paracrine pathway. How-
ever, autocrine IL-17A–IL-17RC neutrophil activation has been shown in 
the pathological condition [76]. Thus, a possible autocrine pathway of 
IL-17A-IL-17RC in tumour stromal cells need to be validated in further 
studies. Furthermore, we mainly focus on the potential modulation of 
IL-17A on CD146 positive stromal cells in this study and show a 
co-staining of CD146 with IL-17RC in adenoma/CRC stromal cells. 
However, previous studies have demonstrated an increased expression 
of CD146 in tumour microvessels in breast carcinoma indicated that 
CD146 is a potentially useful prognostic marker for breast cancer [77]. 
Such inconsistent results might be due to the limited sections used for 
double immunofluorescence of CD146/IL-17RC and different antibody 
sources used in the current study. Extension studies with larger samples 
need to be conducted in the future. 
5. Conclusion 
Although exact mechanisms for TH17/IL-17A in promoting ade-
noma/CRC progression and metastasis are so far undetermined, how-
ever taken together with previous findings, current observations along 
the adenoma–carcinoma sequence could suggest a potential modulatory 
effect of TH17/IL-17A on stromal reaction and cellular response, which 
might provide a supportive environment for the initiation and pro-
gression of CRC. In the future, the blocking efficacy of IL-17 signal in 
modulating stromal components involved in the adenoma-carcinoma 
transition and the process of metastasis should be evaluated. 
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